Crinetics Pharmaceuticals Inc (CRNX) Expected to Announce Quarterly Sales of $250,000.00
Equities research analysts expect that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will announce sales of $250,000.00 for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Crinetics Pharmaceuticals’ earnings, with estimates ranging from $100,000.00 to $550,000.00. The firm is expected to report its next quarterly earnings results on Wednesday, June 12th.
On average, analysts expect that Crinetics Pharmaceuticals will report full year sales of $1.04 million for the current fiscal year, with estimates ranging from $420,000.00 to $2.20 million. For the next fiscal year, analysts anticipate that the business will post sales of $0.00. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. The company had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $0.32 million. Crinetics Pharmaceuticals had a negative net margin of 1,117.52% and a negative return on equity of 38.38%.
In other Crinetics Pharmaceuticals news, major shareholder Ventures Iv L.P. 5Am sold 154,839 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $24.25, for a total value of $3,754,845.75. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Vivo Capital Fund Viii, L.P. sold 417,000 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $22.25, for a total transaction of $9,278,250.00. The disclosure for this sale can be found here.
Large investors have recently bought and sold shares of the company. Rhumbline Advisers acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter worth $254,000. TIAA CREF Investment Management LLC acquired a new position in shares of Crinetics Pharmaceuticals during the 3rd quarter worth $268,000. Vanguard Group Inc. acquired a new position in shares of Crinetics Pharmaceuticals during the 3rd quarter worth $7,103,000. Bank of New York Mellon Corp acquired a new position in shares of Crinetics Pharmaceuticals during the 3rd quarter worth $453,000. Finally, Emory University acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter worth $2,577,000. 69.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of CRNX opened at $25.07 on Tuesday. The firm has a market capitalization of $626.28 million and a price-to-earnings ratio of -11.24. Crinetics Pharmaceuticals has a 1 year low of $19.23 and a 1 year high of $42.00.
Crinetics Pharmaceuticals Company Profile
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.
Featured Story: Why Invest in Dividend Achievers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.